HNSCC Subtyping via Gene Expression Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for classifying head and neck squamous cell carcinoma (HNSCC) subtypes do not effectively incorporate molecular characteristics, particularly those associated with Human Papillomavirus (HPV) infection, limiting their utility in predicting treatment responses and patient management.
Innovation Solution
A method involving the detection of specific classifier biomarkers using gene expression analysis, including qRT-PCR and RNA sequencing, to categorize HNSCC tumors into subtypes such as basal, mesenchymal, classical, and HPV-associated subtypes, enabling more informed prognosis and treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional classification methods are used, then the classification process is simple, but the precision of subtype identification and treatment response prediction is insufficient
Solution Approach 1:
The patent transforms the classification approach by changing from traditional histological parameters to molecular parameters (gene expression profiles, mutational profiles, protein expression). This allows precise identification of four distinct HNSCC subtypes (basal, classical, mesenchymal, and HPV-associated) with specific molecular signatures, thereby improving measurement precision while accepting increased complexity in the classification process
Solution Approach 2:
The patent creates molecular copies or signatures of tumor subtypes through gene expression profiling and mutational analysis. These molecular profiles serve as fingerprints that accurately replicate the biological characteristics of each subtype, enabling precise classification without relying solely on traditional morphological assessment
2Reliability
If molecular characteristics are incorporated, then treatment response prediction improves, but the ease of operation decreases
Solution Approach 1:
The patent performs preliminary molecular characterization of tumors through gene expression analysis and mutational profiling before treatment decisions are made. By establishing molecular subtypes in advance, the system enables more reliable treatment response predictions and allows clinicians to select appropriate therapies based on molecular profile rather than waiting for treatment outcomes
Solution Approach 2:
The patent introduces molecular biomarkers and gene expression profiles as intermediary indicators between tumor morphology and treatment response. These molecular intermediaries provide mechanistic insights into tumor biology and serve as predictive markers for treatment efficacy, bridging the gap between traditional classification and treatment outcomes
Data Source
AI summary
Methods and compositions are provided for determining a subtype of head and neck squamous cell carcinoma (HNSCC) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for HNSCC. Also provided herein are methods and compositions for determining the response of an individual with a HNSCC subtype to a therapy such as immunotherapy.